Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

APGN - Apexigen Inc

IEX Last Trade
0.39
0.390   100.000%

Share volume: 0
Last Updated: Tue 22 Aug 2023 07:44:45 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 4.47%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
-53.04%
Key data
Stock price
$0.39
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
N/A - N/A
52 WEEK CHANGE
N/A
MARKET CAP 
10.039 M
YIELD 
N/A
SHARES OUTSTANDING 
24.661 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.65
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO:
Region: US
Website:
Employees: 29
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by apximab™, the company’s proprietary antibody drug discovery platform. its lead immuno-oncology drug candidate, apx005m, is a potent immune-activating antibody against cd40 currently in phase 2 clinical development.

Recent news